<DOC>
	<DOC>NCT00654745</DOC>
	<brief_summary>To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.</brief_summary>
	<brief_title>18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics</brief_title>
	<detailed_description>This is a single group study in which participants were titrated to the next of 6 regimens if blood pressure (BP) goals were not met.</detailed_description>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Amlodipine Besylate, Olmesartan Medoxomil Drug Combination</mesh_term>
	<criteria>Males or females aged 18 to 80 years. Diagnosis of type 2 diabetes mellitus and on a stable regimen of any oral antidiabetic agent(s) for at least 3 months, with or without adjunctive use of Byetta (exenatide); Note: Subjects diagnosed with type 2 diabetes mellitus who were not on oral antidiabetic agents may have been enrolled if they had a documented history of type 2 diabetes by American Diabetes Association criteria, including the specific plasma glucose results listed below: Fasting plasma glucose &gt;=126 mg/dL (7.0 mmol/L); or Symptoms of hyperglycemia and a casual (any time of day without regard to time since last meal) plasma glucose &gt;=200 mg/dL (11.1 mmol/L). The classic symptoms of hyperglycemia were considered to include polyuria, polydipsia, and unexplained weight loss; or Twohour plasma glucose &gt;=200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test; Newly diagnosed hypertension or uncontrolled hypertension (defined as SBP &gt;130 mmHg and/or DBP &gt;80 mmHg) on current antihypertensive monotherapy or combination therapy. Subjects must fulfill mean seated office blood pressure parameters at two consecutive, qualifying visits during the placebo runin phase, and, subsequently, daytime ambulatory blood pressure monitoring (ABPM) criteria. Females should not be pregnant or lactating and, if applicable, using adequate contraception. Subjects with uncontrolled hypertension taking multiple antihypertensive therapies (at the discretion of the investigator). Type 2 diabetes mellitus with a glycosylated hemoglobin A1c (HbA1c) &gt;=9.0% at screening; Subjects with type 1 or type 2 diabetes mellitus requiring insulin. Subjects with any serious disorder which may limit the ability to evaluate the safety and efficacy of study medication, or subjects with secondary hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>blood pressure reduction</keyword>
</DOC>